<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">

Champions Oncology


Recent Posts

Champions Oncology Reports Record Quarterly Revenue of $11.3 Million

Sep 14, 2021 2:33:55 PM / by Champions Oncology

Hackensack, NJ – September 13, 2021Champions Oncology, Inc. (Nasdaq: CSBR), leaders in transformative technology solutions utilized in drug discovery and development, today announced its financial results for its first quarter of fiscal 2022, ended July 31, 2021.

First Quarter and Recent Highlights: 

  • Record quarterly revenue of $11.3 million, an increase of 18% year over year
  • Reported non-GAAP income from operations, excluding stock-based compensation, depreciation and amortization, of $422,000
  • Validated 6 therapeutic discovery targets

Read More →

Champions Oncology Announces an Expanded Corporate Strategy to Include Drug Discovery and Development

Jul 26, 2021 8:50:14 AM / by Champions Oncology

Hackensack, NJ – July 26, 2021Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, announced today an expansion of its corporate strategy as they unveil their entry into the drug discovery and development space. Champions is organized as a dynamic ecosystem of business units centered around a world leading oncology research center that is based off a unique & proprietary set of data and experimental platforms. The corporate composition of the company includes three business units (1) the foundational Research Services Business, (2) the recently launched Research Software Business with its flagship product, Lumin Bioinformatics, and (3) the newly announced Discovery and Innovation Business.

Read More →

Champions Oncology Reports Quarterly Revenue of $10.6 Million

Jul 23, 2021 1:22:26 PM / by Champions Oncology

Hackensack, NJ - July 22, 2021 Champions Oncology, Inc. (NASDAQ:CSBR), engaged in creating transformative technology solutions to be utilized in drug discovery and development, today announced its financial results for the year and fourth fiscal quarter ended April 30, 2021.

Fourth Quarter and Fiscal Year 2021 Financial and Recent Business Highlights:

  • Record annual revenue of $41.0 million, an increase of 28% year-over-year

  • Developed in house computational target discovery expertise to discover novel therapeutic targets

  • Continued expansion of our Lumin SaaS platform

Read More →

Champions Oncology and BGI Americas Announce a Strategic Partnership to provide Mass Spectrometry Proteomics, Metabolomics, and multi-omic Data Analysis Solutions

Jun 15, 2021 9:15:31 AM / by Champions Oncology

Hackensack, NJ – June 15, 2021 –Champions Oncology (NASDAQ: CSBR), a technology-enabled research organization announced today that they have entered into a strategic partnership with BGI Americas.

Through this partnership, BGI will now have access to Champions’ Lumin Bioinformatics platform, a revolutionary data interpretation tool, to display and deliver proteomics data to their clients. By leveraging Lumin, BGI’s customers will be able to gain novel insights from their proteomics data using unique multi-omic datasets assembled from over 25,000 cancer patients. Lumin Bioinformatics allows oncology scientists and bioinformaticians to analyze and visualize cancer model public and proprietary datasets to illuminate the cellular dynamics of cancer, through specialized modules such as gene signatures, network viewers, synergy plots and even gene dependency mapper tools using AI machine learning technology.

Read More →

Champions Oncology Reports Record Quarterly Revenue of $10.8 Million

Mar 12, 2021 5:56:30 PM / by Champions Oncology

Hackensack, NJ – March 11, 2021 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery and development through data-driven research strategies and innovative pharmacology, biomarker and data platforms, today announced its financial results for the third fiscal quarter ended January 31, 2021.

Third Quarter and Recent Highlights:

  • Delivered record quarterly revenue of $10.8 million, an increase of 20% year over year
  • Reported non-GAAP income from operations, excluding stock-based compensation, depreciation and amortization, of $1.3 million
  • Expanded Lumin Bioinformatics proprietary SaaS platform with proteomic module integration
Read More →